ArticleInflammatory bowel diseases2023
Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study.
Article in Inflammatory bowel diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07121920 (A Prospective Study Evaluating Ex-vivo Confocal Imaging of Fluorescent Tagged Monoclonal Antibodies and Proteomic Profiles of Biopsied Tissue to Predict Therapeutic Response Among Children and Adolescents With Inflammatory Bowel Disease), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study Evaluating Ex-vivo Confocal Imaging of Fluorescent Tagged Monoclonal Antibodies and Proteomic Profiles of Biopsied Tissue to Predict Therapeutic Response Among Children and Adolescents With Inflammatory Bowel Disease
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Effect of Kono-S anastomosis on reducing postoperative recurrence rates in Crohn's disease: a systematic review and meta-analysis.Techniques in coloproctology · 2024Pooled it
- Artificial intelligence in endoscopy related to inflammatory bowel disease: A systematic review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Pooled it
- Review
- Artificial intelligence in inflammatory bowel disease: From current evidence, clinical translation, and the road to precision medicine.Chinese medical journal · 2026Review
- Histologic signatures as predictors of intestinal barrier impairment in inflammatory bowel disease: integration with endoscopic and molecular markers.Journal of Crohn's & colitis · 2026Article
- Artificial intelligence in inflammatory bowel disease: bridging innovation, implementation and impact.Nature reviews. Gastroenterology & hepatology · 2026Review
- New Technologies for IBD Endoscopy.Journal of clinical medicine · 2026Review
- Artificial intelligence in the management of inflammatory bowel disease: What's next?World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Real-time microscopic visualisation: current applications and challenges of confocal laser endomicroscopy in the diagnosis and treatment of small bowel disorders.Therapeutic advances in gastroenterology · 2026Review
- Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.Therapeutic advances in gastroenterology · 2026Review
- Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease: endo-histo-barrier-omics study.Journal of Crohn's & colitis · 2025Article
- Artificial intelligence in inflammatory bowel disease: Current applications and future directions.World journal of gastroenterology · 2025Review
- Artificial Intelligence in Advancing Inflammatory Bowel Disease Management: Setting New Standards.Cancers · 2025Review
- Artificial intelligence in inflammatory bowel disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Review
- Artificial Intelligence in Inflammatory Bowel Disease Endoscopy.Diagnostics (Basel, Switzerland) · 2025Review
- How Artificial Intelligence Will Transform Clinical Care, Research, and Trials for Inflammatory Bowel Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Review
- Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel disease.Frontiers in immunology · 2025Review
- Artificial intelligence in advanced endoscopic imaging: transforming optical diagnosis in gastroenterology.Frontiers in medicine · 2025Review
- Rediscovering histology - the application of artificial intelligence in inflammatory bowel disease histologic assessment.Therapeutic advances in gastroenterology · 2025Review
- Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence.United European gastroenterology journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to predict response to biologics in inflammatory bowel disease (IBD) using computerized image analysis of probe confocal laser endomicroscopy (pCLE) in vivo and assess the binding of fluorescent-labeled biologics ex vivo. Additionally, we investigated genes predictive of anti-tumor necrosis factor (TNF) response.
methodsTwenty-nine patients (15 with Crohn's disease [CD], 14 with ulcerative colitis [UC]) underwent colonoscopy with pCLE before and 12 to 14 weeks after starting anti-TNF or anti-integrin α4β7 therapy. Biopsies were taken for fluorescein isothiocyanate-labeled infliximab and vedolizumab staining and gene expression analysis. Computer-aided quantitative image analysis of pCLE was performed. Differentially expressed genes predictive of response were determined and validated in a public cohort.
resultsIn vivo, vessel tortuosity, crypt morphology, and fluorescein leakage predicted response in UC (area under the receiver-operating characteristic curve [AUROC], 0.93; accuracy 85%, positive predictive value [PPV] 89%; negative predictive value [NPV] 75%) and CD (AUROC, 0.79; accuracy 80%; PPV 75%; NPV 83%) patients. Ex vivo, increased binding of labeled biologic at baseline predicted response in UC (UC) (AUROC, 83%; accuracy 77%; PPV 89%; NPV 50%) but not in Crohn's disease (AUROC 58%). A total of 325 differentially expressed genes distinguished responders from nonresponders, 86 of which fell within the most enriched pathways. A panel including ACTN1, CXCL6, LAMA4, EMILIN1, CRIP2, CXCL13, and MAPKAPK2 showed good prediction of anti-TNF response (AUROC >0.7).
conclusionsHigher mucosal binding of the drug target is associated with response to therapy in UC. In vivo, mucosal and microvascular changes detected by pCLE are associated with response to biologics in inflammatory bowel disease. Anti-TNF-responsive UC patients have a less inflamed and fibrotic state pretreatment. Chemotactic pathways involving CXCL6 or CXCL13 may be novel targets for therapy in nonresponders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.